Lung Cancer News and Research

Latest Lung Cancer News and Research

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

29 Sep 2010

Circulating tumor cells may be promising alternative for tumor biopsies

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

Researchers identify biomarker to predict tivozanib drug resistance

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

29 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.

29 Sep 2010

IsoRay reports increase revenue for 2010 fiscal year

IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.

28 Sep 2010

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.

28 Sep 2010

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a randomized, controlled, investigator sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.

27 Sep 2010

Concerted effort yields significant progress in reducing depression, HIV/AIDS, and osteoporosis in women

A concerted effort to boost research on women's health over the last two decades has lessened the burden of disease and reduced deaths among women due to cardiovascular disease, breast cancer, and cervical cancer, says a new report from the Institute of Medicine. The effort has yielded less but still significant progress in reducing the effects of depression, HIV/AIDS, and osteoporosis on women, added the committee that wrote the report.

24 Sep 2010

NCCN launches series of guidelines on cancer treatment

Patients with cancer and their caregivers have a new resource to help them navigate the maze of treatment options that they often confront. Today at the NCCN Patient Advocacy Summit in Washington D.C., the National Comprehensive Cancer Network launched its new series of NCCN Guidelines for Patients, consumer-friendly translations of the NCCN Clinical Practice Guidelines in Oncology outlining appropriate cancer treatment.

24 Sep 2010

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG in pancreatic cancer, the company announced today.

24 Sep 2010

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that the National Cancer Institute has purchased Caliper's Quantum FX, a stand-alone microCT system for pre-clinical imaging, to study spontaneous tumor models in lung cancer.

23 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.

22 Sep 2010

UT MD Anderson Cancer Center aims to reduce tobacco use among at-risk youths in SE Texas

The University of Texas MD Anderson Cancer Center is reaching out to southeast Texas via an interactive, arcade-style video game aimed at reducing tobacco use among at-risk teens and adolescents.

22 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Gen-Probe announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its PROGENSA® PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer.

22 Sep 2010

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.

22 Sep 2010

ARRA's legacies may solve challenges related to health, energy and environment

The presidents of six leading research universities and two higher-education associations joined Vice President Joe Biden and White House science advisor Dr. John Holdren this morning to discuss the scientific research and related activities that have been made possible by the American Recovery and Reinvestment Act (ARRA).

22 Sep 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

Circulating tumor cells may be promising alternative for tumor biopsies

Researchers identify biomarker to predict tivozanib drug resistance

Researchers discover new diagnostic test for prostate cancer

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

IsoRay reports increase revenue for 2010 fiscal year

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

Concerted effort yields significant progress in reducing depression, HIV/AIDS, and osteoporosis in women

NCCN launches series of guidelines on cancer treatment

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

Scientists develop new therapy for treatment of skin, lung cancer

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

UT MD Anderson Cancer Center aims to reduce tobacco use among at-risk youths in SE Texas

AACR to host fourth International Conference on Molecular Diagnostics

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

ARRA's legacies may solve challenges related to health, energy and environment

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in